CLN-049: A New and Differentiated Approach to Acute Myeloid Leukemia Treatment
CLN-049 is a T cell engager currently being evaluated in clinical studies for individuals living with AML.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Management of Acute Myeloid Leukemia: A Review
- Treatment of Acute Myeloid Leukaemia
- Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
- Research blog: Accelerating progress in AML
- Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012